四川头面部自主神经分布电动模型海口脑及脑动脉分布模型,鹤岗高级成人鼻腔吸痰及护理模型,郑州缝合练习模块综合包,河南马胃解剖模型,呼和浩特泪道冲洗操作训练模型,揭阳高178CM 针灸铜人模型,柳州表面血管结扎止血模型

LOS ANGELES, Sept. 1 (Xinhua) -- Fisker Automotive, a Southern California electric car maker, announced on Thursday that it has signed a pact with BMW regarding the supply of engines and other related components for future models in a major tieup.The Anaheim, Orange County-based U.S. car maker will get a four-cylinder turbocharged engine, totalling 100,000 units every year, for its next generation of cars under a project code-named "Project Nina," the company said.The production of the model, a mass-market plug-in hybrid sedan, will begin at the end of 2012 and the sale is slated for 2013."The BMW engine was an obvious choice for us, as BMW is known for producing the best and most fuel efficient gasoline engines in the world," Fisker's CEO and Executive Design Director Henrik Fisker said. "We are very pleased to have signed this agreement with BMW."The firm did not disclose the terms.The U.S. automaker, founded in 2007, has produced electric vehicles with extended range (EVer). The first derivative of "Project Nina" will be a mid-sized premium sedan which utilizes the technology.The company's other products include Fisker Karma Sedan, a luxury sports car and the world's first premium electric plug-in hybrid.

WASHINGTON, June 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Monday unveiled in a report a new strategy to meet the challenges posed by rapidly rising imports of FDA- regulated products and a complex global supply chain.The report, titled "Pathway to Global Product Safety and Quality," calls on the agency to transform the way it conducts business and to act globally in order to promote and protect the health of U.S. consumers.According to the report, the FDA will partner with its counterparts worldwide to create global coalitions of regulators focused on ensuring and improving global product safety and quality. The coalitions of regulators will develop international data information systems and networks, and increase the regular and proactive sharing of data and regulatory resources across world markets.The FDA will build in additional information gathering and analysis capabilities with an increased focus on risk analytics and information technology. It increasingly will leverage the efforts of public and private third parties and industry and allocate FDA resources based on risk."FDA regulated imports have quadrupled since 2000. The FDA and our global regulatory partners recognize this new reality and realize we must work proactively and collaboratively to address the challenges we face," FDA Commissioner Margaret Hamburg said in a statement. "The FDA must further collaborate and leverage in order to close the gap between our import levels and our regulatory resources. This report is an important step in ensuring we are able to fulfill our critical public health mission."

LOS ANGELES, July 27 (Xinhua) -- The Juno spacecraft of the National Aeronautics and Space Administration (NASA) arrived at its launch pad at the Cape Canaveral Air Force Station in Florida on Wednesday, ready for a mission to Jupiter to study the solar system, the Jet Propulsion Laboratory (JPL) said.The solar-powered, Jupiter-bound spacecraft was secured into place on top of its rocket at 10:42 a.m. EDT (7:42 a.m. PDT), said JPL in Pasadena, California.Juno will arrive at Jupiter in July 2016 and orbit its poles 33 times to learn more about the gas giant's interior, atmosphere and aurora, according to JPL."We're about to start our journey to Jupiter to unlock the secrets of the early solar system," said Scott Bolton, the mission 's principal investigator from the Southwest Research Institute in San Antonio, Texas. "After eight years of development, the spacecraft is ready for its important mission."Now that the Juno payload is atop the most powerful Atlas rocket ever made -- the United Launch Alliance Atlas V 551 -- a final flurry of checks and tests can begin and confirm that all is go for launch, according to JPL.The final series of checks begins Wednesday with an on-pad functional test. The test is designed to confirm that the spacecraft is healthy after the fueling, encapsulation and transport operations."The on-pad functional test is the first of seven tests and reviews that Juno and its flight team will undergo during the spacecraft's last 10 days on Earth," said Jan Chodas, Juno's project manager at JPL. "There are a number of remaining pre- launch activities that we still need to focus on, but the team is really excited that the final days of preparation, which we've been anticipating for years, are finally here. We are ready to go. "The launch period for Juno opens Aug. 5, 2011, and extends through Aug. 26. For an Aug. 5 liftoff, the launch window opens at 11:34 a.m. EDT (8:34 a.m. PDT) and remains open through 12:43 p.m. EDT (9:43 a.m. PDT), JPL said.Managed by JPL, the Juno mission is part of the New Frontiers Program managed at NASA's Marshall Space Flight Center in Huntsville, Alaska.

STOCKHOLM, July 7 (Xinhua) -- A patient has been given a new trachea made from a synthetic scaffold seeded with his own stem cells in a Stockholm's hospital, the Swedish medical university Karolinska Institutet said on Thursday.The operation was performed on June 9th at Karolinska University Hospital in Huddinge and the patient, a 36-year old man, has been well on the way to recovery and would be discharged from the hospital on Friday, the university said in a statement.The patient had been suffering from late stage tracheal cancer with the tumor had reached approximately 6cm in length and was extending to the main bronchus.Since no suitable donor windpipe was available, the transplantation of the synthetic tissue engineered trachea was performed as the last possible option for the patient.The successful transplantation of tissue engineered synthetic organs, referred to as regenerative medicine, could open promising therapeutic possibilities for the thousands of patients who suffer from similar conditions.Transplantations of tissue engineered windpipes with synthetic scaffolds in combination with the patient's own stem cells as a standard procedure means that patients would not have to wait for a suitable donor organ.This would be a substantial benefit for patients since they could benefit from earlier surgery and have a greater chance of cure, according to the statement.

BEIJING, August 4 (Xinhuanet) -- Medtronic Inc. is giving Yale University a 2.5 million U.S. dollar grant to review the safety and effectiveness of its controversial spine treatment called Infuse Bone Graft, according to The Wall Street Journals Thursday.Under terms of the pact, the company will release to Yale and eventually the public what participants described as an unprecedented amount of clinical trial and other data. The university will select two research teams from other organizations to perform separate analyses of the data.The announcement comes in the wake of a paper in June in the Spine Journal. The paper revealed that several clinical studies of Infuse, conducted by surgeons with strong economic ties to Medtronic, failed to report serious complications that arose in the trials. The critical paper also found that many of the studies were designed in ways in favor of Infuse over a treatment given to a control group.Medtronic disputes some of the findings and is conducting an internal investigation of the matter.Infuse accounts for about 700 million dollars in annual sales for Medtronic. The product is under investigation by the Senate Finance Committee over the role payments to physicians who may have played how studies were reported.